Related Experiment Video
Updated: May 6, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a
Lulin Zeng1, Yan Xiang1, Ao Sun1
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Objective:
Immunotherapy has made significant progress in the treatment of advanced non-small cell lung cancer (NSCLC). However, treatment options for driver gene-negative patients remain limited. This study evaluated the efficacy and safety of Cadonilimab (AK104), a bispecific PD-1/CTLA-4 antibody, in this population.
Methods:
We retrospectively analyzed real-world data from driver gene-negative advanced NSCLC patients treated with AK104. Outcomes included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).
Results:
Among 30 patients, AK104 combination therapy achieved an ORR of 23.3%, DCR of 80%, and median PFS (mPFS) of 6.3 months. The combination of AK104 with chemotherapy and other anti-angiogenic inhibitors (AAI) achieved a notable mPFS of 11.1 months. First-line treatment (n=12) yielded ORR 50%, DCR 100%, and mPFS 13.3 months; second-line (n=6) ORR 16.7%, DCR 100%, mPFS 7.7 months; beyond second-line (n=12) ORR 0%, DCR 50%, mPFS 2.6 months. No significant difference in mPFS was observed between PD-L1-positive and PD-L1-negative patients (4.5 vs. 3.0 months, P = 0.76). Common adverse events included anemia (66.7%), leukopenia (63.3%), neutropenia (56.7%), and thrombocytopenia (53.3%), with grade 3 events in 16.7%. One patient discontinued due to immune-related pancreatitis, and no deaths occurred.
Conclusions:
This study confirms the promising efficacy and acceptable safety profile of AK104 combination therapy in patients with driver gene-negative advanced NSCLC. These findings collectively support the need for further large-scale prospective studies to validate its clinical utility.
Insights
Cadonilimab (AK104) shows promise for advanced non-small cell lung cancer (NSCLC) patients lacking driver mutations. This bispecific antibody offers a new immunotherapy option with manageable side effects.
Area of Science:
- Oncology
- Immunotherapy
- Lung Cancer Research
Background:
- Immunotherapy has advanced non-small cell lung cancer (NSCLC) treatment.
- Limited options exist for advanced NSCLC patients with driver gene-negative status.
Purpose of the Study:
- To evaluate the efficacy and safety of Cadonilimab (AK104), a bispecific PD-1/CTLA-4 antibody.
- To assess AK104 in patients with advanced, driver gene-negative NSCLC.
Main Methods:
- Retrospective analysis of real-world data.
- Included patients with advanced NSCLC negative for driver gene mutations treated with AK104.
- Evaluated outcomes: objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS).
Main Results:
- AK104 combination therapy showed an ORR of 23.3% and DCR of 80% with a median PFS (mPFS) of 6.3 months.
- Combination with chemotherapy and anti-angiogenic inhibitors (AAI) resulted in an mPFS of 11.1 months.
- First-line treatment demonstrated superior outcomes (ORR 50%, mPFS 13.3 months). Common adverse events included anemia and leukopenia; one case of immune-related pancreatitis.
Conclusions:
- Cadonilimab (AK104) combination therapy demonstrates promising efficacy and acceptable safety in driver gene-negative advanced NSCLC.
- Findings support further large-scale prospective studies to confirm clinical utility.
- AK104 represents a potential new immunotherapy avenue for this patient subgroup.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
